Sun Pharmaceutical Industries Limited
SUNPHARMA
Rangering i aksjer
#526
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Aksjekurs
$19.24
Markedsverdi
$46.15B
Endring (1 dag)
-0.97%
Endring (1 år)
0.84%
Land
IN
Handel Sun Pharmaceutical Industries Limited (SUNPHARMA)
Kategori
Healthcare
EPS for Sun Pharmaceutical Industries Limited (SUNPHARMA)
EPS per June 2026 TTM: $0.56
Ifølge de siste økonomiske rapportene og aksjekursen til Sun Pharmaceutical Industries Limited er selskapets nåværende EPS (TTM) $0.56. Ved slutten av 2024 hadde selskapet en EPS på $0.48, en økning sammenlignet med EPS-en i 2023 som var $0.43.
EPS-historikk for Sun Pharmaceutical Industries Limited fra 2004 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $0.56 | 4.96% |
| 2025 | $0.53 | 11.41% |
| 2024 | $0.48 | 11.35% |
| 2023 | $0.43 | 139.18% |
| 2022 | $0.18 | 8.71% |
| 2021 | $0.17 | -20.64% |
| 2020 | $0.21 | 30.19% |
| 2019 | $0.16 | 15.61% |
| 2018 | $0.14 | -69.05% |
| 2017 | $0.45 | 56.75% |
| 2016 | $0.29 | -5.81% |
| 2015 | $0.30 | 19.44% |
| 2014 | $0.25 | -4.30% |
| 2013 | $0.27 | 4.58% |
| 2012 | $0.25 | 29.09% |
| 2011 | $0.20 | 35.66% |
| 2010 | $0.14 | -16.31% |
| 2009 | $0.17 | -7.39% |
| 2008 | $0.19 | 94.07% |
| 2007 | $0.10 | 38.62% |
| 2006 | $0.07 | 41.63% |
| 2005 | $0.05 | 19.51% |
| 2004 | $0.04 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CH
|
